profit from every $100 of sales.
$0$100
ResMed
$239.53+0.27% today
-5.0% in 1 year
1-year low $182.821-year high $275.96
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2021 to 2026.
0%20% a year
You pay $22.12 for every $1 of profit it makes in a year.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What ResMed sold, what it kept, and what it did with the cash.
Sales went from $4.22 billion in 2023 to $5.65 billion in 2026, with $1.52 billion of profit last year.
SalesProfit
ResMed vs. similar companies
ResMed grows the fastest of these 5 and is the cheapest for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| ResMed | 22.1× · Fair price | ||
 West Pharmaceutical Services | 58.8× · Expensive | ||
 Hologic | 30.0× · Fair price | ||
 Baxter International | No profit yet | ||
 The Cooper Companies | 31.8× · Expensive |
AI analysis
An AI analyst reads ResMed's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| 3,197 | 3,578 | 4,223 | 4,685 | 5,146 | 5,653 | |
| 1,839 | 2,024 | 2,356 | 2,655 | 3,055 | 3,452 | |
| 904 | 1,002 | 1,152 | 1,320 | 1,687 | 1,887 | |
| 1,110 | 1,177 | 1,350 | 1,530 | 1,923 | 2,120 | |
| 475 | 779 | 898 | 1,021 | 1,401 | 1,523 | |
| 3.24 | 5.30 | 6.09 | 6.92 | 9.51 | 10.43 | |
| 57.5% | 56.6% | 55.8% | 56.7% | 59.4% | 61.1% | |
| 28.3% | 28.0% | 27.3% | 28.2% | 32.8% | 33.4% | |
| 14.8% | 21.8% | 21.3% | 21.8% | 27.2% | 26.9% |
Balance sheet
| In millions of USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Total assets | 4,728 | 5,096 | 6,752 | 6,872 | 8,174 | 8,966 |
| Cash | 295 | 274 | 228 | 238 | 1,209 | 1,469 |
| Total debt | 794 | 918 | 1,580 | 874 | 852 | 826 |
| Total liabilities | 1,842 | 1,735 | 2,622 | 2,008 | 2,207 | 2,381 |
| 2,886 | 3,361 | 4,130 | 4,864 | 5,968 | 6,585 | |
| 146 | 147 | 147 | 148 | 147 | 146 | |
| 19.5% | 18.1% | 15.9% | 18.2% | 19.5% | 20.1% | |
| 16.4% | 23.2% | 21.7% | 21.0% | 23.5% | 23.1% |
Cash flow
| In millions of USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| 737 | 351 | 693 | 1,401 | 1,752 | 1,806 | |
| – | 156 | 134 | 115 | 101 | – | |
| – | 195 | 559 | 1,286 | 1,651 | – | |
| Dividends paid | 227 | 245 | 258 | 282 | 311 | 350 |
| – | 0 | 0 | 150 | 300 | 700 | |
| 64 | 65 | 71 | 80 | 92 | 104 |
Valuation
- 22.1×
- 21.6×
- 0.84
- 4.6×
- 6.0×
- 20.4×
- 15.6×
- 4.9%
- 4.5%
- 1.1%
Profitability
- 61.1%
- 33.4%
- 26.9%
- 38.0%
- 19.6%
- 17.0%
- 24.4%
- 17.3%
- 25.5%
- 6.5%
Growth
- +12.1%
- +26.3%
- +29.2%
- +7.7%
- +0.2%
Financial health
- -0.3×
- 0.13
- 9.6%
- 65.4×
- 3.01
- 2.33
- 0.63
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 9%of 946
Top 8%of 872
Top 36%of 563
Top 47%of 868
Top 22%of 986
What analysts expect
- Average price target
- $281.29
- Range
- $225.00 – $345.00
- 3 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Apr 30, 2026 | 2.86 | 2.79 | +2.5% |
| Jan 29, 2026 | 2.81 | 2.74 | +2.6% |
| Oct 30, 2025 | 2.55 | 2.51 | +1.6% |
| Jul 31, 2025 | 2.55 | 2.55 | +0.0% |
| Apr 23, 2025 | 2.37 | 2.38 | −0.4% |
| Jan 30, 2025 | 2.43 | 2.32 | +4.7% |
| Oct 24, 2024 | 2.20 | 2.04 | +7.8% |
| Aug 1, 2024 | 2.08 | 2.07 | +0.5% |
1.1%of the share price, paid each year
On $1,000 invested$11a year at today's yield, before tax
+7.7%2020 to 2025
Raised10 yearsin a row, in our data
Paid per share, each year
$1.16 in 2015 → $2.26 in 2025
How safe it looks
23.0% of its profit
Room to growStretchedMore than it earns: 18.8%
News
What Sent ResMed Stock Lower?Yahoo Finance · Nov 2, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
6/7Passes 6 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
84Pass
Benjamin Graham
68Pass
Philip Fisher
95Pass
Peter Lynch
91Pass
Joel Greenblatt
47No pass
Charlie Munger
88Pass
Terry Smith
87Pass
Questions about ResMed
Is ResMed a good stock to buy?
A strong, very profitable business at a fair price. 6 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the ResMed AI analysis
What does ResMed do?
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It is in Medical - Instruments & Supplies, based in San Diego, CA, United States, with 10,600 employees.
Does ResMed pay a dividend?
Yes. At today's price the dividend is 1.1% a year, about 23% of its yearly profit. In 2026 it paid out $350 million in dividends.
Is ResMed stock halal?
Yes. ResMed passes our halal screen: its business is permitted and its debt is 2% of its market value, under the 30% limit. How we check
How has ResMed stock done over the past year?
Down 5.0% over the past twelve months, to $239.53. It traded between $182.82 and $275.96 and is 13.2% below its high.
Who are ResMed's competitors?
The largest listed companies in the same industry are West Pharmaceutical Services, Hologic, Baxter International and The Cooper Companies. The peers table on this page compares their profit, growth and price with ResMed's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.